ARIAD Announces Commercial Availability of Iclusig for Patients with Refractory Philadelphia-Positive Leukemias in US

By: Benzinga
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA ) today announced the commercial availability of Iclusig^® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.